drugset / Trial / NCT04398303
ACT-20 in Patients With Severe COVID-19 Pneumonia
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is determine the safety and efficacy of ACT-20-MSC (allogenic human umbilical derived mesenchymal stem cells) and ACT-20-CM (allogenic human umbilical derived mesenchymal stem cells in conditioned media) in patients with moderate to severe COVID-19 pneumonia.
Timeline
- Start
- 2020-05
- Primary completion
- 2020-10
- Completion
- 2020-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACT-20-CM | Unknown | 100 ml | Intravenous |
| Subject | ACT-20-MSC | Cell therapy | 1e+06 cells/kg | Intravenous |